share_log

Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75

Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75

Maxim集團以買入評級啓動對Avenue Therapeutics的報道,宣佈目標股價爲0.75美元
Benzinga ·  2023/12/11 09:43

Maxim Group analyst Jason McCarthy initiates coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and announces Price Target of $0.75.

Maxim集團分析師傑森·麥卡錫以買入評級開始對Avenue Therapeutics(納斯達克股票代碼:ATXI)進行報道,並宣佈目標股價爲0.75美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論